Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition
Author:
Affiliation:
1. Department of Dermatology and Allergy, School of Medicine Technical University of Munich Munich Germany
Publisher
Wiley
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.62
Reference15 articles.
1. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments
2. Pyoderma gangrenosum
3. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial
4. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
5. Selective Janus kinase inhibitors come of age
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Outcomes of JAK Inhibitor Therapy in Pyoderma Gangrenosum: A Systematic Review;Journal of Cutaneous Medicine and Surgery;2024-08-28
2. Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review;Rheumatology International;2024-03-15
3. Use of Baricitinib in a patient with treatment-resistant pyoderma gangrenosum;SAGE Open Medical Case Reports;2024-01
4. Treatment of Pyoderma Gangrenosum;Dermatologic Clinics;2023-12
5. JAK Inhibitor Use for the Inpatient Dermatologist;Current Dermatology Reports;2023-11-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3